

News Release

Jill DeCoste
+1 978 715 4670
jill.decoste@emdmillipore.com

September 28, 2015

EMD Millipore Publishes White Paper Highlighting Importance of Emerging Biotech Companies for Discovery of New Drugs During Recent Emerging Biotech Executive Summit

- **Paper focuses on strategies to advance molecules and bring lifesaving drugs to market faster**
- **Purpose is to encourage and continue open dialogue around investments, partnerships and building value on the road to clinic**
- **Summit sessions led by executives in alliance management, in-licensing and venture funding**

Billerica, Massachusetts, September 28, 2015 – [EMD Millipore](#), the Life Science business of [Merck KGaA](#) of Darmstadt, Germany, today announced that it has published an original white paper, recognizing the impact the emerging biotech community has on the future of healthcare.

The paper is based on discussions during the company's Emerging Biotech Executive Summit on June 15, 2015 in Philadelphia. At the event, forty biotech leaders from across the USA, representing over one hundred molecules, came together to have an open dialogue around the emerging biotech community, early-stage investments and partnerships as well as how to build value, credibility, and recognition on the road to clinic. This white paper builds upon that discussion.

As a partner of the life science industry, EMD Millipore recognizes the impact the emerging biotech community has on the future of healthcare. Udit Batra, President and CEO of EMD Millipore, reinforced the company's commitment to this community during his opening presentation at the summit.

News Release

“Emerging biotech companies are a critical component and source of innovation, helping to bring groundbreaking drug products to market. These companies could capture a much higher share of value by bringing new molecules further along the development track,” says Batra.

By building upon the panel discussions that were initiated at the summit, EMD Millipore’s new white paper provides insights from executives in alliance management, in-licensing and venture funding around the challenges that these companies face, including limited capabilities, expertise and funding, and insight on how to conquer them. It is a valuable source of information for any emerging biotech firm looking for strategies of how to best push their molecules through the pipeline and ultimately to market.

Visit www.emdmillipore.com/ebsummit to download the white paper.

About EMD Millipore

EMD Millipore is the U.S. Life Science subsidiary of Merck KGaA, Darmstadt, Germany. As part of the global Life Science business of Merck KGaA, Darmstadt, Germany, EMD Millipore offers a broad range of innovative, performance products, services and business relationships that enable our customers’ success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the life science tools industry, the Life Science business of Merck KGaA, Darmstadt, Germany, serves as a strategic partner to customers and helps advance the promise of life science. Headquartered in Billerica, Massachusetts, the global business has around 10,000 employees, operations in 66 countries and 2014 revenues of €2.7 billion.

For more information, please visit www.emdmillipore.com.

About EMD Serono

EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, is a leading U.S. biopharma company focused exclusively on specialty care. For more than 40 years, EMD Serono has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono has more than 1,100 employees around the country with commercial, clinical and research operations based in the company’s home state of Massachusetts.

For more information, please visit <http://www.emdserono.com/en/index.html>.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck KGaA, Darmstadt, Germany, is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day.



News Release

For more information, please visit www.emdgroup.com.